[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase 2/3Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR) Containing a Ritinavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects.

What is the purpose of the study? (in Layman's terms, please describe the study)

To confirm the dose and evaluate the safety and tolerability of ritonavir-boosted elvitegravir (EVG/r) in HIV-1 treatment-experienced subjects aged 4 weeks to less than 18 years of age. The dose of EVG will be determined by intensive pharmacokinetic sampling at Day 10. The safety and antiviral activity of EVG will also be evaluated.

Upstate Institutional Review Board (IRB) Number:


Study/Protocol ID:


Study Phase:


Patient Age Group:


Principal Investigator:

Leonard B Weiner

ClinicalTrials.Gov ID:


For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Wendy A Holz
Phone: 315-464-7562
Email: holzw@upstate.edu

Return to Previous Page || Search Again